Cases & Deals

MacroGenics raises $45 million in Series C round

Clients MacroGenics, Inc.

Jones Day represented MacroGenics, Inc., a company focused on product development derived from in-house discoveries in the areas of oncology, autoimmune disorders, inflammation, allergy, and infectious diseases, in its issuance of $45 million of Series C Preferred Stock in a private placement to Ventures West, Caisse de dépôt et placement du Québec, RiverVest Venture Partners, Biogen Idec New Ventures, Texas Pacific Group (TPG) Ventures, Alta Partners, InterWest Partners, MPM Capital, Mithra Ventures, OrbiMed Advisors, and Red Abbey Venture Partners.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.